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The prevalence of type 2 diabetes mellitus (T2DM) is increasing and it is estimated that by
2030 approximately 366 million people will be diagnosed with this condition. The use of
dipeptidyl peptidase IV (DPP-IV) inhibitors is an emerging strategy for the treatment of
T2DM. DPP-IV is a ubiquitous aminodipeptidase that cleaves incretins such as glucagon
like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), resulting
in a loss in their insulinotropic activity. Synthetic DPP-IV drug inhibitors are being used
to increase the half-life of the active GLP-1 and GIP. Dietary intervention is accepted as
a key component in the prevention and management of T2DM. Therefore, identification
of natural food protein-derived DPP-IV inhibitors is desirable. Peptides with DPP-IV inhibi-
tory activity have been identified in a variety of food proteins. This review aims to provide an
overview of food protein hydrolysates as a source of the DPP-IV inhibitory peptides with
particular focus on milk proteins. In addition, the proposed modes of inhibition and structure–
activity relationship of peptide inhibitors are discussed. Milk proteins and associated pep-
tides also display insulinotropic activity and help regulate blood glucose in healthy and
diabetic subjects. Therefore, milk protein derived peptide inhibitors may be a unique
multifunctional peptide approach for the management of T2DM.
Dipeptidyl peptidase IV inhibition: Type 2 diabetes mellitus: Bioactive peptide: Glucagon
like peptide-1: Glucose-dependent insulinotropic polypeptide: Milk protein: Hydrolysate:
Functional foods
Type 2 diabetes mellitus (T2DM) is a chronic metabolic
disorder that is characterised by impaired insulin
secretion and insulin resistance. There is an increasing
global burden of this disease and it is estimated that by
2030 approximately 366 million individuals worldwide
will be diagnosed with T2DM(1). T2DM is a complex
disease and there are many co-morbidities and compli-
cations associated with it including obesity, hyper-
tension, high cholesterol, CVD and renal failure(2).
Therefore, effective strategies to manage T2DM should
not only address hyperglycaemia but also prevent further
progression of the disease and its associated
complications.
In recent years, novel strategies for the treatment of
T2DM have been proposed. Many of them focus on
the use of incretin therapies including glucagon like pep-
tide 1 (GLP-1) analogues, GLP-1 receptor agonists and
dipeptidyl peptidase IV (DPP-IV) inhibitors. GLP-1
and glucose-dependent insulinotropic polypeptide (GIP)
are incretin hormones that stimulate the release of insulin
from the pancreas in a glucose-dependent manner(3).
Both peptides are natural substrates for the enzyme
DPP-IV and are rapidly degraded in vivo resulting in
loss of their insulinotropic activity(4). Therefore,
DPP-IV inhibitors protect incretins from enzyme clea-
vage and increase the half-life of the active hormones.
DPP-IV inhibitors (commonly knownas gliptins) are an
emerging drug class and can be classified, based on their
structure, as peptidomimetics or non-peptidomimetic
inhibitors(5). Peptidomimetic compounds are designed
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to mimic the N-terminal dipeptide that is cleaved by
DPP-IV. Vildagliptin (Galvus®, Novartis) and
Saxagliptin (Onglyza™, Bristol Meyers, Squibb) are
both peptide-like inhibitors that are approved for use in
the European Union and the USA, respectively.
Linagliptin (Tradjenta™, Boehringer Ingelheim) and
Sitagliptin (Januvia, Merck) are non-peptidomimetics
approved for use in the USA, and Alogliptin
(SYR-322, Takeda Pharmaceutical Co.) another non-
peptidomimetic is approved for use in Japan. Most syn-
thetic DPP-IV inhibitors are generally well tolerated;
however, some adverse effects of gliptin-based com-
pounds have been reported including headaches, urinary
and upper respiratory tract infections(6).
Dietary intervention is accepted as a key component in
the prevention and management of T2DM(7). The health
enhancing properties of dietary proteins and their con-
stituent peptides are well recognised(8). These bioactive
peptides are short peptide sequences, typically less than
ten amino acids, encrypted within the structure of a
food protein and which can be released by enzyme
hydrolysis, microbial fermentation or physical and
chemical processing. Once released, the peptides can
interact with specific receptors and regulate a variety of
physiological functions. In particular, milk protein-
derived peptides have beneficial effects on the cardio-
vascular, gastrointestinal, immune and nervous systems(9).
Whey proteins (WP) and caseins (CN) may aid in mini-
mising the physiological effects of T2DM and have
been shown to stimulate insulin secretion and regulate
blood glucose in T2DM subjects(10,11). Recent research
has also shown that peptides derived from milk proteins
have DPP-IV inhibitory properties(12,13). The purpose of
this review is to consider the role of food protein-derived
peptides as potential inhibitors of DPP-IV. While the
primary focus is milk protein-derived peptide inhibitors,
other food protein-derived peptide inhibitors are also
taken into consideration in order to advance our under-
standing of this topic. The application of milk protein-
derived DPP-IV inhibitory peptides will be considered
in the context of a nutritional strategy for the manage-
ment of T2DM.
Incretin hormones
The incretin effect is the augmentation of insulin
secretion elicited by hormones secreted within the gastro-
intestinal tract in response to nutrient ingestion(3). This
phenomenon was demonstrated when oral ingestion of
glucose resulted in a greater level of insulin secretion
compared with a glucose load delivered through infu-
sion(14,15). In healthy subjects, there was a significant
augmentation of the insulin response following oral glu-
cose ingestion, approximately threefold higher than the
response to glucose infusion. This phenomenon is
explained by the existence of gut-derived factors that
enhance glucose-stimulated insulin secretion from pan-
creatic β-cells. During a meal, incretins, GLP-1 and
GIP, are released within the small intestine and act as
the primary regulators of glucose homoeostasis(16).
However, in T2DM the incretin response is diminished
and equates to approximately 50% of the response
achieved in a healthy adult(17). Post-prandial secretion
of GLP-1 is blunted in T2DM, contributing to the
reduced insulinotropic response(18). While there is no
difference in the secretion level of GIP it has been
suggested that the body’s response to the insulinotropic
actions of this hormone is diminished(19). The reduced
response to the insulinotropic actions of GIP may be
related to a reduction in receptor expression or reduced
β-cell sensitivity to GIP(20).
GLP-1 is a pro-glucagon derived peptide produced in
the enteroendocrine (L) cells, which are predominantly
found in the lower portion of the small intestine.
L-cells are nutrient sensitive and GLP-1 is secreted in
response to glucose(21), proteins(22,23) peptides(24),
amino acids(25,26) and lipids(27). It has been suggested
that the magnitude of the GLP-1 response is related to
the extent of exposure of the gut mucosa to the ingested
nutrient(28). GLP-1 is released into the circulation in its
active form, GLP-1(seven to thirty-six amide) but has a
short half-life (2–4min). Active GLP-1 is rapidly
degraded by DPP-IV, which cleaves the N-terminal
dipeptide (His–Ala), producing the inactive GLP-1(nine
to thirty-six amide)(29). Approximately 10% of the active
GLP-1 reaches the systemic circulation(30). In addition to
its insulin secretion properties, GLP-1 has also been
shown to inhibit glucagon secretion(31), both factors con-
tributing to the glucoregulatory properties of the hor-
mone. Other physiological effects of GLP-1 (Fig. 1)
include inhibition of gastric acid secretion(32), decreased
gastric emptying(33), enhanced satiety and decreased
food intake(34).
GIP is a forty-two amino acid peptide which is
released from duodenal K cells in the proximal small
intestine. It is secreted in response to nutrient (fat and
carbohydrate) ingestion(35) and rises within the first
5–10min of the post-prandial period and peaks between
30 and 60min after nutrient ingestion. Circulating GIP is
a combination of the active GIP (one to forty-two) and
inactive GIP (three to forty-two) peptide, produced by
cleavage of the N-terminal dipeptide (Tyr–Ala) by
DPP-IV. In addition to the incretin effect, GIP is also
involved in the regulation of fat metabolism (Fig. 1),
having a direct effect on adipoyctes to promote TAG
storage(36). Post-prandial plasma concentrations of GIP
are approximately tenfold higher than GLP-1(30). Some
infusion studies have suggested that GLP-1 has greater
insulinotropic potency than GIP(19,31). However, the
differences in concentration and potency seem to have
a compensatory effect as it has been demonstrated that
both hormones act cooperatively with respect to their
incretin effect(19,37).
Incretin hormone action is regulated through specific
receptors (GLP-1R and GIP-R). Both G-protein coupled
receptors are expressed in a variety of tissues. GLP-1
receptors are expressed on pancreatic β- and α-cells
whereas GIP receptors are found only on β-cells(3). In
addition, GIP receptors are expressed on adipose tissue
and GLP receptors in the heart, lung, brain, gastrointes-
tinal tract, peripheral and central nervous system.
Dipeptidyl peptidase IV inhibitory peptides 35
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Binding of GLP-1 or GIP to their receptor activates
intracellular signalling mechanisms, which causes an
elevation of cAMP and an increase in protein kinase
A. GIP and GLP-1 can act synergistically with glucose
to close ATP-sensitive K+ channels. This facilitates
membrane depolarisation leading to an increase in in-
tracellular calcium and ultimately insulin release via
exocytosis of insulin containing granules(38).
Mice lacking DPP-IV had improved blood glucose
regulation and lower degradation of GIP and
GLP-1(39). DPP-IV deficient rats had better glucose toler-
ance, increased insulin and higher concentrations of
active GLP-1(40). Furthermore, DPP-IV knockout mice
did not develop glucose intolerance or diabetes even
after 20 weeks on a high-fat diet(41). In human subjects,
chemical inhibitors of DPP-IV have been used to prevent
the degradation of intact incretins in both healthy(42) and
T2DM subjects(43). In healthy adults, treatment with
Vildaglitin increased active GLP-1 concentration two-
to threefold relative to the placebo and inhibited
DPP-IV activity for up to 95% for 4h. In the T2DM
patients, 4 weeks treatment with the DPP-IV inhibitor
(LAF237) significantly increased basal and post-prandial
active GLP-1 concentration by approximately 50 % rela-
tive to the placebo. Meanwhile, plasma DPP-IV activity
was significantly inhibited approximately 99 % at 4h and
was inhibited by 60 % after 24h. Post-prandial glucose
concentrations were significantly lower which correlated
with the reduction in plasma glucagon; however, there
was no effect on plasma insulin. Therefore, DPP-IV
plays an important role in the regulation of incretin hor-
mone metabolism and glucose homoeostasis. The appli-
cation of natural compounds that inhibit the activity of
this enzyme could represent a useful strategy to increase
the half-life of active incretin hormones.
Structure and function of dipeptidyl peptidase IV
DPP-IV, also known as adenosine deaminase binding
protein or CD26 (EC 3.4.14.5), is a ubiquitous aminodi-
peptidase. It is expressed on the surface of several cell
types including lymphocytes, monocytes and in tissues
from the pancreas, kidney, liver and gastrointestinal
tract. Soluble DPP-IV is found in plasma and cerebro-
spinal fluid. The widespread expression of DPP-IV
GLP-1 7-36
GIP 1-42
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Fig. 1. (Colour online) Physiological functions of the active incretin hormones, glucagon like peptide 1 (GLP-1)
and glucose-dependent insulinotropic polypeptide (GIP) and the relationship between incretin hormones and dipeptidyl
peptidase IV (DPP-IV) activity.
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suggests that it is associated with a variety of physiologi-
cal functions including immunoregulation(44), endocrine
activity and the degradation of peptide hormones(45).
The immunological activities of DPP-IV such as T-cell
stimulation, which rely on protein binding, are mediated
by the external surface of the enzyme(46). The enzymatic
incretin degradation and immunological functions of
DPP-IV are located at different sites within the
enzyme(44) which suggests that these functions may be
independent of one another.
DPP-IV is a dimeric, transmembrane, glycoprotein
(220kDa–2×110kDa subunits). Each subunit is
anchored in the plasma membrane by a hydrophobic
helix consisting of seven N-terminal amino acids. The
large globular extracellular domain contains a flexible
segment linked to a glycosylated region, followed by a
cysteine-rich region, linked to C-terminal catalytic region
which contains a catalytic triad consisting of Ser–Asp–
His residues (Fig. 2).
The C-terminal catalytic region contains the active site
sequence, Gly–Trp–Ser–Tyr–Gly, which has serine exo-
peptidase activity. The three-dimensional structure of
DPP-IV determines substrate specificity for proteolytic
cleavage(6). The enzyme active site forms a hydrophobic
pocket within the interior of the folded structure; there-
fore, only elongated peptides or unfolded proteins can
access this region. The active site is accessible in two
ways, via an opening in the β-propeller domain or via a
large side opening formed at the interface of the
β-propeller and α/β hydrolase domain(47). The structural
features of DPP-IV suggest that the most likely entrance
to the active site is via the large side opening(48). This is
the shortest and most directly accessible route to the
active site. The negative charge of this domain attracts
peptides with a positively charged N-terminus. In
addition, if the peptide enters via the large side opening
it will be correctly orientated for cleavage. It has also
been proposed that a secondary binding site exists within
the structure of DPP-IV. These binding sites can influ-
ence catalytic activity of DPP-IV in particular the selec-
tivity of the enzyme towards the substrate(49). The
specificity for the amino acid located at position P1
decreases with increasing substrate length. Peptide bind-
ing to the secondary binding site is influenced by the
amino acid sequence at the N-terminal region of the pep-
tide in particular at positions P4–P8.
The widespread expression of DPP-IV means that it
can easily access and inactivate a wide variety of biologi-
cal regulatory peptides, including GIP, GLP-1, growth
hormone, peptide YY and neuropeptide Y(45). DPP-IV
has a relatively strict substrate specificity and principally
cleaves proline (Xaa–Pro; where Xaa is any amino acid)
or alanine (Xaa–Ala) containing dipeptides from the
N-terminal of a polypeptide (Fig. 3). While Pro or Ala
are preferred at position P1 lower cleavage rates exist
for peptides containing Ser, Gly, Val and Leu in this pos-
ition(29,50). Hydrophobic and basic residues at position P2
increase the susceptibility for cleavage compared with
acidic residues. Peptides containing Pro or hydroxyl-
proline at position P1′ are not cleaved. Kinetic studies
Fig. 2. Main structural features of human dipeptidyl peptidase IV(45).
Reproduced with permission from Elsevier.
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Fig. 3. (Colour online) Specificity of substrate cleavage by
dipeptidyl peptidase IV.
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have shown that optimal cleavage rates occur between
pH 7·5 and 8·5 and at 37 °C(45).
Mode of action of dipeptidyl peptidase IV inhibitors
The mode of action of DPP-IV inhibitors is schemati-
cally illustrated in Fig. 4. Natural substrates of
DPP-IV, including GLP-1, associate with the active site
(Fig. 4a). If GLP-1 is in the correct configuration state
it will be locked into the active site forming a GLP-1:
DPP-IV complex. The peptide bond between amino
acids at positions P1 and P1′ will be weakened
(51). The
bond is rapidly degraded and the inactive GLP-1 dis-
sociates from the active site. The overall kinetics of this
process are determined by the rate limiting step, which
is dissociation from the active site. Diprotin A (Ile–
Pro–Ile) and B (Val–Pro–Ile), originally isolated from
the culture filtrates of Bacillus cereus BMF673-RF1,
are two examples of substrate type inhibitors of
DPP-IV with half-maximal inhibitory concentration
(IC50) values in the micromolar range
(52).
A typical competitive enzyme inhibitor will compete
with a natural substrate for binding to the active site.
Competitive enzyme inhibitors (Fig. 4b) generally follow
Michaelis–Menten kinetics with dose-dependent activity
and IC50 values in the micro to pico molar range
(45).
A number of peptides have been shown to act as com-
petitive inhibitors of DPP-IV. In particular, Pro-
containing peptides (e.g. Ile–Pro) have been shown to
have IC50 values in the low micromolar range
(53). A
second mechanism of competitive inhibition has been
proposed(51). This involves formation of an enzyme–
inhibitor complex (Fig. 4c). This substrate enzyme com-
plex binds the active site of DPP-IV. The association
causes the compound to be locked into the active site.
The rate of dissociation from the active site occurs at a
slower rate than for the standard competitive inhibitor,
resulting in a more prolonged DPP-IV inhibition. This
type of substrate-like enzyme blocker inhibition has
been proposed as a mechanism of action for the synthetic
inhibitor Vildagliptin(51,54).
Non-competitive inhibitors can interact with secondary
binding sites (e.g. receptor sites and substrate recognition
site) in the native structure of the DPP-IV molecule(55).
This binding modifies the substrate specificity and cata-
lytic activity of DPP-IV. Longer peptides (thirty to fifty
amino acids) have been shown to act as non-competitive
inhibitors by forming interactions at the dimerisation
interface and blocking the formation of the DPP-IV active
dimer(56). Amino acid substitutions at specific locations
within the peptide can alter the mode of inhibition and
potency of inhibition(13,57). In addition, there is some evi-
dence that the peptides can function by mixed modes of
inhibition(57). This may involve the binding of two inhibi-
tor compounds at two different sites on the enzyme.
Food protein-derived dipeptidyl peptidase IV
peptide inhibitors
Proteins and peptides have a wide variety of biological
activities that may benefit human health. In particular,
bioactive peptide with beneficial effects on the cardio-
vascular, gastrointestinal, immune and nervous systems
have been identified(58). The bioactivity of these peptides
is typically related to their amino acid sequence and
size(59). As already mentioned, recent research has ident-
ified food protein-derived peptides with DPP-IV inhibi-
tory activity(60).
Fig. 4. (Colour online) Binding kinetics for (a) natural substrates of dipeptidyl peptidase IV (DPP-4) and
(b, c) potential mechanisms of DPP-IV inhibition(51). GLP-1, glucagon like peptide 1. Reproduced with
permission from John Wiley & Sons.
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Enzyme hydrolysates of Atlantic salmon skin gelatin
have been shown to possess DPP-IV inhibitory activity
and this activity was dependent on the specificity of the
enzyme used to generate the hydrolysate(61). The most
potent hydrolysate was generated using Flavorzyme®
and the resulting hydrolysate had 45 % DPP-IV inhi-
bition at 5·0mg/ml. Further molecular mass fraction-
ation, yielded a <1kDa fraction, which had 61 %
DPP-IV inhibition at 2·0mg/ml and an IC50 value of
1·35mg/ml. This low-molecular-weight fraction was
further purified by reversed-phase high-performance
liquid chromatography and the most potent fraction
had an IC50 value of 0·57mg/ml. Within this fraction,
two DPP-IV inhibitory peptides were identified (Gly–
Pro–Gly–Ala and Gly–Pro–Ala–Glu; Table 1) which
had IC50 values of 49·6 and 41·9μM, respectively.
Hydrolysis of the East Asian azuki bean with proteo-
lytic or microbial enzymes produced hydrolysates with
Table 1. Food protein hydrolysate derived peptides with dipeptidyl peptidase IV inhibitory activity
Substrate Sequence IC50 (μM) Reference
Atlantic salmon skin Gly–Pro–Gly–Ala 49.6 (61)
Gly–Pro–Ala–Glu 41.9
Tuna cooking juice Pro–Gly–Val–Gly–Gly–Pro–Leu–Gly–Pro–Ile–Gly–Pro–Cys–Tyr–Glu 116 (62)
Cys–Ala–Tyr–Gln–Trp–Gln–Arg–Pro–Val–Asp–Arg–Ile–Arg 78
Pro–Ala–Cys–Gly–Gly–Phe–Tyr–Ile–Ser–Gly–Arg–Pro–Gly 96.4
Japanese rice bran Leu–Pro 2400 (53)
Ile–Pro 410
Met–Pro 870
Val–Pro 880
Arg–Pro 2240
Thr–Pro 2370
Leu–Pro 2370
Lys–Pro 2540
His–Pro 2820
Tyr–Pro 3170
Phe–Pro 3630
Trp–Pro 4530
Pro–Pro 5860
Ser–Pro 5980
Ala–Pro 7950
Gly–Pro NA
Pro–Ile NA
Gouda cheese Leu–Pro–Gln–Asn–Ile–Pro–Pro–Leu 46 (63)
Leu–Pro–Gln–Asn–Ile–Pro–Pro 160
Pro–Gln–Asn–Ile–Pro–Pro–Leu 1500
Leu–Pro–Gln 82
Val–Pro–Ile–Thr–Pro–Thr 130
Val–Pro–Ile–Thr–Pro–Thr–Leu 110
Phe–Pro–Gly–Pro–Ile–Pro–Asp 260
Pro–Gly–Pro–Ile–His–Asp–Ser 1000
Ile–Pro–Pro–Leu–The–Gln–Thr–Pro–Val 1300
Val–Pro–Pro–Phe–Ile–Gln–Pro–Glu 2500
Tyr–Pro–Phe–Pro–Gly–Pro–Ile–Pro–Asp 670
β-lactoglobulin Val–Ala–Gly–Thr–Trp–Tyr 174 (64)
β-lactoglobulin Ile–Pro–Ala 49 (65)
β-lactoglobulin Ile–Pro–Ala–Val–Phe 45 (66)
Ile–Pro–Ala–Val–Phe–Lys 143
Val–Leu–Val–Leu–Asp–Thr–Asp–Tyr–Lys 424
Thr–Pro–Glu–Val–Asp–Asp–Glu–Ala–Leu–Glu–Lys 320
Milk protein Glu–Lys 3216 (13)
Gly–Leu 2615
Ala–Leu 882
Val–Ala 168
Trp–Val 65
Phe–Leu 399
His–Leu 143
Ser–Leu 2517
IC50, half-maximal inhibitory concentration; NA, no inhibitory activity.
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DPP-IV inhibitory properties(67). The most potent hydro-
lysate of azuki bean was generated using Umanizyme G®
and was further fractionated through a 10kDa mem-
brane. The resulting permeate had 52% DPP-IV inhi-
bition at 1·0mg/ml. Bioinformatic analysis predicted
that the Native American amaranth protein contains
peptides that have DPP-IV inhibitory activity(68).
Tryptic digests of amaranth produced hydrolysates with
dose-dependent increase in inhibitory activity and
which had IC50 values between 1·2 and 2·0mg/ml
(56).
Removal of the larger protein/peptide material by ultra-
filtration (10kDa) increased the DPP-IV inhibitory
activity by 50–100 % and the 10kDa ultrafiltration
permeates had IC50 values between 1·0 and 1·6mg/ml.
In silico analysis of the amaranth globulins with tryspin
identified four peptides, which contained thirteen to
fifty amino acid residues (11S amaranth globulin f
(1–13), f(18–39), f(69–81), f(92–143)) and which may be
responsible for the inhibitory activity. Hydrolysates
derived from hen’s egg displayed DPP-IV inhibitory
activity(69). The inhibitory activity varied depending on
the specificity of the enzyme used, with up to fourfold
differences in the IC50 values (e.g. 1·5 v. 0·4mg/ml) for
lysozyme hydrolysates.
Japanese rice bran has also been used to generate
peptides with DPP-IV inhibitory properties(53). Two
hydrolysates were prepared using fungal and bacterial
enzyme preparations (Umanizyme G® and Bioprase
SP) and had IC50 values of 2·3 and 26·4mg/ml, respect-
ively. The tenfold difference in the inhibitory activity
further highlights the importance of the enzyme specifi-
city used to release DPP-IV inhibitory peptides. The
Umanizyme G® hydrolysate was further purified by gel
filtration chromatography followed by reversed-phase
HPLC and two DPP-IV inhibitory dipeptides (Leu–Pro
and Ile–Pro) were identified (Table 1). Tuna cooking
juice has been used to generate peptides with DPP-IV
inhibitory activity. Hydrolysates were generated using
two fungal endoproteinases in order to establish the opti-
mal conditions to generate DPP-IV inhibitory pep-
tides(62). Maximum cleavage of peptides occurred after
1–2h of hydrolysis and DPP-IV inhibition was 40–45 %
at 10·0mg/ml. Hydrolysates were further purified by
gel filtration chromatography (40 % inhibition at
5·0mg/ml) and reversed-phase HPLC (∼60% inhibition
at 5·0mg/ml) in order to enrich for peptides with
DPP-IV inhibitory activity. Three peptides (Pro–Gly–
Val–Gly–Gly–Pro–Leu–Gly–Pro–Ile–Gly–Pro–Cys–Tyr–
Glu, Cys–Ala–Tyr–Gln–Trp–Gln–Arg–Pro–Val–Asp–
Arg–Ile–Arg and Pro–Ala–Cys–Gly–Gly–Phe–Tyr–Ile–
Ser–Gly–Arg–Pro–Gly) with molecular mass between
1304 and 1690Da, isolated from a tuna cooking juice
hydrolysate, were determined to be responsible for the
DPP-IV inhibitory activity (Table 1). Synthetic peptides
matching these sequences displayed a dose-dependent
increase in DPP-IV inhibition with IC50 values between
78 and 116μM. These peptide sequences contained thir-
teen to fifteen amino acid residues, making them longer
than typical DPP-IV inhibitory peptides. There were
some structural similarities between the three peptides,
each peptide contained at least one Pro residue and all
the peptides had a high proportion of hydrophobic
amino acid residues.
Simulated gastrointestinal digestion of the three tuna
cooking juice-derived peptides had up to 22% higher
DPP-IV inhibitory activity following simulated gastro-
intestinal digestion(62). This suggests that the longer pep-
tides were degraded to smaller fragments producing a
greater number of peptides with inhibitory activity and/
or more potent peptides. The intestinal stability of the
DPP-IV inhibitory peptides can be assessed using
amino acid clustering models(70). This predicts stability
of a peptide under simulated intestinal digestion and
was recently used to evaluate the stability of a potent
DPP-IV inhibitory peptide, Trp–Val. This peptide was
classified as neutral, that is, between 25 and 75% of
the peptide was predicted to remain intact after 60min
of simulated intestinal digestion. Free amino acids,
with the exception of Leu, Met and Trp, did not inhibit
DPP-IV. Some dipeptides containing these amino acids
were shown to be inactive (e.g. Arg–Trp, Val–Trp and
Ile–Trp), whereas other peptides (e.g. Trp–Val, Phe–
Leu and His–Leu) were more potent DPP-IV inhibitors
than the constituent amino acids. It was therefore
suggested that depending on their intestinal stability the
DPP-IV inhibitory properties of dipeptide inhibitors
may be increased or decreased in vivo(71).
Milk protein-derived peptide inhibitors
Milk is a good source of nitrogen and essential amino
acids. The major protein components of milk, CN
(80%) and WP (20%), are suitable precursors to generate
DPP-IV inhibitory peptides(60). CN is the predominant
protein in milk and is composed of αS1-, αS2-, β- and
κ-CN(72). CN have a relatively open and disordered
structure which makes them highly susceptible
to proteolysis. In addition, CN contain a large amount
of Pro residues with abundances of 16·7, 11·8, 8·5
and 4·8% for β-, κ-, αS1- and αS2-CN, respectively
(8).
Therefore, CN-derived peptides are likely to contain
the Xaa–Pro motif within their sequences. This increases
the susceptibility to cleavage by DPP-IV or other post
Pro cleaving enzymes and the potential for the release
of peptides with DPP-IV inhibitory activity. CN protein
hydrolysates enriched in short peptides have been shown
to inhibit DPP-IV activity(73). Candidate inhibitory pep-
tides were identified within the hydrolysates and these
peptides had IC50 values between 5 and 121μM. The
most potent sequence was Leu–Pro–Leu which had an
IC50 value of 5μM. There were some structural simi-
larities between the potent CN-derived DPP-IV inhibi-
tory peptides as they generally contained a Pro residue
located in the P1–4 N-terminal region and predominantly
as the penultimate residue. In addition, hydrophobic
amino acid residues Leu, Val and Phe were typically
located close to the Pro residue. DPP-IV inhibitory
peptides have been isolated from a water-soluble
extract of a Gouda-type cheese(63). The most potent
peptide was an octapeptide (β-CN f70–77, Table 1)
which had an IC50 value of 46μM. Peptide derivatives:
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Leu–Pro–Gln–Asn–Ile–Pro–Pro, Pro–Gln–Asn–Ile–Pro–
Pro–Leu and Leu–Pro–Gln had lower inhibitory activity
(Table 1) suggesting that the amino acid sequence is an
important determinant of activity.
WP have a globular structure and are composed of five
major proteins: β-lactoglobulin (β-Lg), α-lactalbumin
(α-La), bovine serum albumin, immunoglobulins and a
number of minor proteins such as lactoferrin (LF) and
lactoperoxidase. Each individual WP has different phys-
icochemical properties, which can be modified by enzy-
matic hydrolysis and hydrolysis of WP has been
shown to release DPP-IV inhibitory peptides(13,64–66).
Digestion of WP with pepsin and pancreatin generated
peptides with DPP-IV inhibitory activity and peptic
digestion produced the most potent hydrolysate with an
IC50 value of 0·075mg/ml. However, the peptides respon-
sible for the activity have not been identified(12). In silico
prediction suggests that β-Lg contains approximately
three times more peptide sequences with potential
DPP-IV inhibitory activity than α-La(60). This was
demonstrated by tryptic digestion of the two major WP
where the β-Lg hydrolysate displayed dose-dependent
DPP-IV inhibition while the α-La hydrolysate had no
inhibitory activity(64). Chromatographic isolation and
purification of the β-Lg hydrolysate enabled identifi-
cation of the active peptide, β-Lg f15–20 (Table 1). The
activity was confirmed using the synthetic peptide
sequence, which also displayed a concentration-
dependent inhibitory effect and had an IC50 value of
174μM.
An LF hydrolysate with DPP-IV inhibitory activity
has been recently identified and this hydrolysate had an
IC50 value of 1·088mg/ml
(13). While the IC50 value was
not significantly different from other WP hydrolysates
this was the first report of an LF hydrolysate with
DPP-IV inhibitory activity. In addition to the DPP-IV
inhibitory activity the LF hydrolysate was also found
to have antioxidant activity. Diabetes is associated with
an increase in oxidative stress(74). Therefore, the LF
hydrolysate may have potential in the management of
T2DM through the multifunctional properties of
DPP-IV inhibition and antioxidant activity.
The DPP-IV inhibitory activity of WP and CN has
been compared(12). In general, CN-derived hydrolysates
had significantly higher DPP-IV inhibitory activity than
WP hydrolysates. In some instances, CN hydrolysates
had twofold higher inhibitory activity than the equi-
valent WP hydrolysate produced with the same enzyme.
For all WP and CN hydrolysates, DPP-IV inhibitory
activity ranged from 15 to 51% (at 0·487mg/ml) and
was dependent on the specificity of the proteolytic
enzyme. The greater level of inhibitory activity in the
CN-derived hydrolysates is in agreement with the fact
that the CN proteins contain a greater proportion
of inhibitory peptide motifs within their primary se-
quence. In another study, CN and WP hydrolysates
were reported to have similar DPP-IV inhibitory
activity(13). The higher than expected IC50 values for
the CN hydrolysates may be due to the fact that not all
possible DPP-IV inhibitory peptides were released during
hydrolysis. Lineweaver and Burk analysis revealed that
all the DPP-IV inhibitory hydrolysates tested were com-
petitive inhibitors of DPP-IV, indicating direct inter-
action of the milk-derived peptides with the active site
of DPP-IV(13).
Milk protein-derived peptides have been shown to pos-
sess DPP-IV inhibitory properties (Table 1). A β-Lg
derived tri-peptide (Ile–Pro–Ala) can be released from
β-Lg by digestion with proteinase K(75) and when evalu-
ated in vitro it was found to have an IC50 value of
49μM(65). This peptide shares some structural similarities
with the reference inhibitor Ile-Pro–Ile although the IC50
value was approximately fourteenfold higher (3·5 v.
49μM for Ile–Pro–Ile and Ile–Pro–Ala, respectively).
Related peptide sequences, Ile–Pro–Ala–Val–Phe and
Ile–Pro–Ala–Val–Phe–Lys had IC50 values of 45 and
143μM, respectively(66). The addition of Val and Phe resi-
dues led to a small reduction of the DPP-IV IC50 value
compared with the truncated peptide Ile–Pro–Ala
(Table 1). However, further addition of a Lys residue
resulted in a threefold increase in the IC50 value
(Table 1) which was attributed to a decrease in peptide
hydrophobicity. This highlights the importance of the
amino acid sequence to the potency of DPP-IV inhi-
bition. Milk protein-derived dipeptides have been studied
for their DPP-IV inhibitory activity(13) and from the
twelve dipeptides studied eight were DPP-IV inhibitors
(Table 1). The most potent peptide identified was Trp–
Val, a non-competitive DPP-IV inhibitor, which had an
IC50 value of 65μM. In addition, Trp–Val had antioxi-
dant properties, which highlight the dual functionality
of some milk-derived peptides.
Structure–activity relationship of peptide inhibitors
The structure–function relationship and the mechanisms
of peptide induced DPP-IV inhibition have not been
fully elucidated. As outlined earlier, the majority of
research conducted to date has focused on the production
and identification of DPP-IV inhibitory peptides from
food protein hydrolysates. However, some structural
characteristics of DPP-IV inhibitory peptides have been
identified. Potent DPP-IV inhibitory peptides typically
contain two to seven amino acid residues with Pro or
Ala as the penultimate amino acid at the N-terminus(73).
It has been shown that the sequence of the peptide rather
than its amino acid composition influences DPP-IV
inhibitory activity. For example, the dipeptides Ile–Pro
and Trp–Val had DPP-IV inhibitory activity (Table 1)
whereas the reverse peptides Pro–Ile and Val–Trp,
respectively had no inhibitory activity(13,53). In addition,
the N-terminal residue of Pro containing dipeptides
(Xaa–Pro) was shown to influence the DPP-IV inhibitory
activity(53). The dipeptide Leu–Pro had a fivefold higher
IC50 value than Ile–Pro (2·37 v. 0·41mM). The dipeptides
Leu–Leu and Val–Val both show DPP-IV inhibitory
activity, however, Leu–Leu–Phe and Leu–Val, did not
have any DPP-IV inhibitory activity(65). This indicates
that the residue present at the N-terminal also influences
inhibitory activity.
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The structural characteristics outlined earlier have
been identified by the analysis of protein hydrolysates
and synthetic peptides. Other methods such as in silico
analysis and molecular docking are complimentary tech-
niques that can also be used to identify potential inhibi-
tory peptides and predict their mechanism of action.
An in silico evaluation of six milk proteins (αS1-, β-, κ-CN,
β-Lg, α-La and LF) found that all proteins contained
DPP-IV inhibitory peptides within their primary
sequence(60). In total, 211 peptide fragments predicted
to have DPP-IV inhibitory activity were found in the
primary sequence of the six milk proteins, Leu–Leu
and Leu–Val occurred most frequently. β-CN had the
greatest proportion (0·249; number of peptides with
activity/number of amino acids residues in the protein)
of peptide sequences with DPP-IV inhibitory activity
while α-La had the lowest (0·041). Such in silico evalu-
ations give an indication of the potential occurrence of
DPP-IV inhibitory peptides within the milk proteins.
However, if enzyme hydrolysis is to be used as an effec-
tive strategy to release DPP-IV inhibitory peptides then
identification of enzymes with appropriate specificity
and selectivity to release the peptides or peptide precur-
sors is essential. In addition, there may be other inhibi-
tory peptide sequences within the milk proteins which
have not yet been identified.
Molecular docking approaches are typically used in
drug discovery(76). More recently, docking strategies
have been used as virtual screening tools to study pep-
tide–enzyme interactions and to predict inhibitory
activity(77). This technique was used to screen dipeptides
for their angiotensin-converting enzyme inhibitory
activity. This has led to the identification of new, potent
angiotensin-converting enzyme-inhibitory dipeptides
(Asp–Trp, Trp–Pro(78)). Molecular docking, with
Autodock Vina, has been utilised to study the interaction
of amino acids and dipeptides with xanthine oxidase and
DPP-IV(71). Docking of competitive, DPP-IV peptide
inhibitors to its active site revealed that interactions
occurred through hydrogen bonds and hydrophobic
interactions. In theory, a low Vina score indicates a
higher binding affinity and would predict a low IC50
value. However, the DPP-IV IC50 values obtained for
the milk-derived dipeptides did not correlate with the cal-
culated peptide Vina scores. As outlined earlier, the
dipeptide Trp–Val was found to be a non-competitive
DPP-IV inhibitor and in agreement with this the peptide
was shown to bind to a secondary binding site outside the
DPP-IV active site.
Docking analysis predicted that for large peptides,
(thirteen to fifty amino acids) derived from tryptic digests
of amaranth protein, the mechanism of binding was
related to the physicochemical properties of the pep-
tide(56). It was proposed that the neutral peptide (11S
amaranth globulin f(1–13)) would bind inside the active
site blocking access to the natural substrates. While
the acidic peptides (11S amaranth globulin f(18–39),
f(69–81) and f(92–143)) were located at the dimerisation
site and blocked formation of the dimeric DPP-IV active
form. The interactions between the DPP-IV and amar-
anth peptides were also principally via hydrophobic
interaction and hydrogen bonds. As indicated earlier,
peptide inhibition of DPP-IV may therefore involve mul-
tiple mechanisms of action. Consequently, an effective
combination of both in silico and empirical approaches
may advance our understanding and discovery of those
structural features essential for potent DPP-IV inhibitory
peptides.
In vivo animal studies
To date, only a small number of animal studies have
evaluated the efficacy of DPP-IV inhibitory hydrolysates
or peptides. The gluco-regulatory effect of a tryptic digest
of β-Lg was evaluated in vivo using mice(64). Animals
received the control (Tris–HCl buffer), β-Lg hydrolysate
(300mg/kg) or Sitagliptin phosphate hydrate (3mg/kg)
30min prior to an oral glucose tolerance test. Over the
2h post-prandial period, the β-Lg hydrolysate decreased
plasma glucose concentrations approximately 14 % rela-
tive to the control. However, it was not as effective as
Sitagliptin, the drug inhibitor of DPP-IV, which pro-
duced a 27 % reduction in plasma glucose relative to
the control. A peptide (Leu–Pro–Gln–Asn–Ile–Pro–
Pro–Leu) derived from Gouda-type cheese which has
shown DPP-IV inhibitory activity in vitro was further
evaluated in vivo in rats(63). The peptide was administered
(300mg/kg) as part of an oral glucose tolerance test
(60mg/ml). During the 2h post-prandial period, adminis-
tration of the peptide reduced plasma glucose by
approximately 30 % relative to the control.
The Zucker, diabetic, fatty rat model of T2DM was
used to evaluate the in vivo bioactivity of an egg lyso-
zyme hydrolysate(69). The hydrolysate and positive con-
trol, Vildagliptin, were administered by oral gavage and
were evaluated over a 6h period. The hydrolysate
resulted in 25 % inhibition of plasma DPP-IV after 90
min and the time-course of the response was similar to
that of Vildagliptin. However, changes in the incretin
hormone levels and glycaemic responses were not
reported. A previous study in Zucker rats reported that
20–30% inhibition of plasma DPP-IV activity was suffi-
cient to increase active GLP-1 and reduce hyperglycae-
mia during an oral glucose tolerance test(79). Therefore,
it may be anticipated that the level of inhibition reported
for the egg lysozyme hydrolysate might induce a similar
response.
A zein protein hydrolysate (ZeinH) has been shown
to increase GLP-1 secretion in mice(24). This activity
was investigated further in rats(80). The ZeinH (500mg)
had glucoregulatory activity when administered prior
to an intraperitoneal glucose (1g/kg) tolerance test.
Administration of the ZeinH resulted in a 2·4-fold
increase in peak plasma insulin and a 23% decrease in
peak plasma glucose relative to the control (meat hydro-
lysate). In addition, the incretin effect was also evaluated
by the changes in total and active GLP-1. The ZeinH
increased active GLP1 (approximately threefold within
15min) relative to the control. Changes in active
GLP-1 were correlated with changes in plasma insulin
and glucose. Finally, administration of the ZeinH was
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found to decrease plasma DPP-IV activity by 20–26%
from basal levels and these concentrations were signifi-
cantly lower than the control. This highlights the poten-
tial multi-functionality (induction of GLP-1 secretion
and decrease in plasma DPP-IV activity) of the ZeinH
which resulted in enhanced insulin secretion and attenu-
ated hyperglycaemia.
The data discussed highlight the potential of food-
derived peptides in the management of T2DM.
However, more detailed human studies are required to
fully evaluate efficacy, safety and potency. In particular,
there is a need for human studies to evaluate milk
protein-derived DPP-IV inhibitors.
Management of type 2 diabetes
The therapeutic application of GLP-1 for the manage-
ment of T2DM was first evaluated in the early 1990s.
At that time, GLP-1 differed from other antidiabetic
agents because the insulinotropic action was stimulated
by nutrient ingestion therefore reducing the risk of hypo-
glycaemia. This led to the development of pharmaco-
logical compounds that targeted the incretin axis and,
in particular, those that enhanced GLP-1 secretion or
increased GLP-1 half-life. As outlined earlier, DPP-IV
is a primary regulator of incretin hormone activity and
this has led to a focus on the use of DPP-IV inhibitors
as a therapeutic strategy.
Synthetic drug inhibitors of DPP-IV have been shown
to lower blood glucose and to prevent inactivation of
GLP-1 and GIP in healthy adults(81,82) and in T2DM
patients(43). In addition, acute ingestion of drug inhibi-
tors (metformin) in T2DM subjects reduced plasma
DPP-IV activity for up to 6h(83). Food protein-derived
peptide inhibitors of DPP-IV are yet to be fully evaluated
in vivo. There is some pre-clinical and clinical evidence
that milk protein and milk protein hydrolysates stimulate
incretin hormone secretion, display insulinotropic
activity and regulate blood glucose in healthy and dia-
betic populations(10,84–86). However, the effect of protein
hydrolysates on plasma DPP-IV activity in human sub-
jects is yet to be evaluated.
Food protein-derived peptide inhibitors of DPP-IV
identified to date have not shown equivalent potency to
synthetic drug inhibitors. Therefore, these inhibitors
may be most suited to combination therapy or as part
of a nutritional intervention strategy in pre-diabetic or
mild diabetic patients. Peptide-drug interactions of
DPP-IV inhibitors have been evaluated in vitro(87).
These combination studies were conducted using the
synthetic drug inhibitor of DPP-IV, Sitagliptin, with
either a WP-derived hydrolysate or dipeptides (Trp–Val
and Val–Ala) with DPP-IV inhibitory activity. These
studies showed that there was an additive effect of
Sitagliptin and the milk-derived peptides on DPP-IV
inhibition. This highlights the potential for combination
(food and drug) therapy, which may be used in the man-
agement of T2DM.
If the DPP-IV inhibitory activity demonstrated in vitro
is to translate in vivo then the bioavailability of the
peptides must also be established. Some DPP-IV peptide
inhibitors identified earlier have shown other bio-
functionalities in vivo. The peptide Ile–Pro–Ala has also
shown antihypertensive properties following oral inges-
tion in rats(75). The efficacy and potency of DPP-IV
inhibitory peptides in human subjects remains to be
established.
Conclusions
The importance and scientific understanding of DPP-IV
activity within incretin hormone biology has increased
rapidly in the last 20 years. Inhibitors of DPP-IV are
now an established therapeutic approach for the treat-
ment of T2DM. However, synthetic drug inhibitors are
not without their limitations and side-effects. Therefore,
there is a growing interest in natural, food-derived pep-
tide inhibitors as these may be effective without display-
ing undesirable side-effects. Much in vitro and some
in vivo works have highlighted the potential of food-
derived peptides as effective DPP-IV inhibitors. Some
food-derived peptide inhibitors have demonstrated
potential to decrease plasma DPP-IV activity, inhibit
degradation of incretin hormones and maintain glucose
homoeostasis in small animals. If the scientific under-
standing and clinical efficacy of these compounds is
further advanced they may offer a unique biofunc-
tional-peptide-based nutritional strategy for use in the
management of T2DM.
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